|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0004827,
umls-concept:C0008976,
umls-concept:C0010802,
umls-concept:C0011900,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0086409,
umls-concept:C0205488,
umls-concept:C0220901,
umls-concept:C0282116,
umls-concept:C0332293,
umls-concept:C0392760,
umls-concept:C0439165,
umls-concept:C0439231,
umls-concept:C0439234,
umls-concept:C0439828,
umls-concept:C0457343,
umls-concept:C0871261,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1306673,
umls-concept:C1542147,
umls-concept:C1552913,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2000-2-7
|
|
pubmed:abstractText |
Interferon-a (IFN) is increasingly being used as the drug of choice in chronic myeloid leukemia patients. The main objectives of the study were to study the influence of the classic prognostic variables and response to IFN, and to assess the influence of this response on the course of the disease and survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:AbadAA,
pubmed-author:ArealCC,
pubmed-author:BenítezEE,
pubmed-author:EscribanoLL,
pubmed-author:Fernández-RañadaJ MJM,
pubmed-author:FerroM TMT,
pubmed-author:García-LarañaJJ,
pubmed-author:GiraldiVV,
pubmed-author:GiraltMM,
pubmed-author:LavilleAA,
pubmed-author:MaldonadoJJ,
pubmed-author:MassaguéII,
pubmed-author:MiguelAA,
pubmed-author:OdriozolaJJ,
pubmed-author:Pérez-EncinasMM,
pubmed-author:Pérez-PonsCC,
pubmed-author:Rodriguez-SalvanésFF,
pubmed-author:SteegmannJ LJL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
978-87
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10553157-Adolescent,
pubmed-meshheading:10553157-Adult,
pubmed-meshheading:10553157-Aged,
pubmed-meshheading:10553157-Basophils,
pubmed-meshheading:10553157-Child,
pubmed-meshheading:10553157-Cytogenetic Analysis,
pubmed-meshheading:10553157-Female,
pubmed-meshheading:10553157-Hematologic Tests,
pubmed-meshheading:10553157-Humans,
pubmed-meshheading:10553157-Interferon-alpha,
pubmed-meshheading:10553157-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:10553157-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:10553157-Leukocyte Count,
pubmed-meshheading:10553157-Male,
pubmed-meshheading:10553157-Middle Aged,
pubmed-meshheading:10553157-Philadelphia Chromosome,
pubmed-meshheading:10553157-Prognosis,
pubmed-meshheading:10553157-Recombinant Proteins,
pubmed-meshheading:10553157-Spain,
pubmed-meshheading:10553157-Survival Rate,
pubmed-meshheading:10553157-Thrombocytopenia,
pubmed-meshheading:10553157-Time Factors,
pubmed-meshheading:10553157-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
|
|
pubmed:affiliation |
Servicio de Hematología, Hospital de la Princesa, Diego de León 62, 28006 Madrid, Spain. fundsteeg@nexo.es.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
